Immunotherapy Single-agent Clinical Trials of atezolizumab, nivolumab, pembrolizumab, avelumab, and durvalumab in various stages of development further subdivided by disease state, into nonmuscle-invasive bladder cancer, muscle-invasive bladder cancer, metastatic first line, and metastatic second line.